Aridis Pharmaceuticals, Inc. filed its 10-K on May 22, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0574 USD | -7.42% | -4.33% | -18.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.12% | 2.75M | |
+9.42% | 115B | |
+11.84% | 106B | |
-14.15% | 21.84B | |
-1.05% | 21.96B | |
-5.29% | 19.21B | |
-38.29% | 17.71B | |
-4.16% | 18.08B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ARDS Stock
- News Aridis Pharmaceuticals, Inc.
- Aridis Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt